IM groupa
| 1 | 2 | 3 | 4 | 5 |
---|
Vaccineb
| Ad-0910G | Ad-0910G + Ad-0910 N | Ad-0910 Gsped | Ad-0910 Gsped + Ad-0910 N | PBS |
Vaccine volume | 0.2 mL | 0.2 mL (0.1 + 0.1 mL) | 0.2 mL | 0.2 mL (0.1 + 0.1 mL) | 0.2 mL |
No. of vaccination | 1 | 1 | 1 | 1 | 1 |
Challenge routec
| IM | IC | IM | IC | IM | IC | IM | IC | IM | IC |
Oral groupd
| 6 | 7 | 8 | 9 | 10 |
Vaccinee
| V-RG | Ad-0910G + Ad-0910 N | V-RG | Ad-0910G + Ad-0910 N | PBS |
Vaccine volume | 0.1 mL | 0.1 mL (0.05 + 0.05 mL) | 0.1 mL | 0.1 mL (0.05 + 0.05 mL) | 0.1 mL |
No. of vaccinationf
| 1 | 1 | 2 | 2 | 1 |
Challenge routeg
| IC | IC | IC | IC | IC |
-
aFifty 4-week-old mice were randomly grouped into 5 groups (ten/group) for intramuscular (IM) vaccination
-
bThe titers of Ad-0910G, Ad-0910Gsped and Ad-0910 N were 108.0 TCID50/mL, 108.0 TCID50/ mL and 107.7 TCID50/mL, respectively
-
cImmunized mice of each group were divided into two subgroup and intramuscularly (IM) and intracranially (IC) challenged with CVS-N2c at 21 days following inoculation of recombinant adenoviruses
-
dThirty 4-week-old mice were divided into 4 groups (five/group) and control group (ten/group) for oral vaccination
-
eThe titers of V-RG (Raboral V-RG®, Merial), Ad-0910G and Ad-0910 N were 107.8 TCID50/mL, 108.0 TCID50/mL and 107.7 TCID50/mL, respectively
-
fMice in the groups 6 and 7 were vaccinated with 0.1 ml of V-RG vaccine or mixed virus (Ad-0910G + Ad-0910 N) via the oral route only once. Mice in the groups 8 and 9 were vaccinated orally once again a week after initial vaccination
-
gAll mice were challenged with CVS-N2c by the IC route 14 days post-vaccination